Pediatric Oncology Subcommittee of the Oncology Drugs Advisory Committee – Food and Drug Administration Open Session Meeting on Optimizing the Development of Oncology and Hematology Drugs for Pediatric Use MK-3475 Pedi - Oncology Drug Advisory Committee - Document - PDFSEARCH.IO

First Page	Meta Content
	Pediatric Oncology Subcommittee of the Oncology Drugs Advisory Committee – Food and Drug Administration Open Session Meeting on Optimizing the Development of Oncology and Hematology Drugs for Pediatric Use MK-3475 Pedi Add to Reading List Open Document File Size: 605,19 KB Share Result on Facebook Company AEs / MSCE Merck Research Laboratories / / Event FDA Phase / / IndustryTerm therapies for childhood cancer / / MedicalCondition childhood cancer / Melanoma IND / abdominal pain / melanoma / Fatigue / Currently underway NSCLC=non-small cell lung cancer / Headache / NSCLC / non-small cell lung cancer / hypothyroidism / dyspnea / Diarrhea / chills / vitiligo / cough / renal failure / Pruritus / pneumonitis / Rash / Nausea / advanced melanoma / / MusicGroup Nausea / / Organization Oncology Drugs Advisory Committee / Food and Drug Administration / Pediatric Oncology Subcommittee / / Person Robert Iannone / / Product Received / Q2W / MK-3475 / / Technology antibodies / / SocialTag Melanoma Ipilimumab Response Evaluation Criteria in Solid Tumors

Pediatric Oncology Subcommittee of the Oncology Drugs Advisory Committee – Food and Drug Administration Open Session Meeting on Optimizing the Development of Oncology and Hematology Drugs for Pediatric Use MK-3475 PediAdd to Reading List